Vita 34 Takes Over Danish StemCare Group

Vita 34 AG, one of Europe’s leading stem cell banks, has successfully completed the acquisition of the
Danish StemCare Group, a prominent player in the field of stem cell storage and regenerative
medicine. This strategic acquisition marks another important step in Vita 34’s ongoing expansion into
key European markets and strengthens its position in the growing regenerative medicine sector.

StemCare Group, based in Denmark, is known for its expertise in the storage and processing of stem
cells, as well as its contributions to the development of advanced therapies. The acquisition of
StemCare will enable Vita 34 to expand its portfolio of services, particularly in the areas of stem cell
banking and the emerging field of regenerative medicine. The integration of StemCare Group’s
operations will enhance Vita 34’s ability to offer innovative therapies and services, making them
more accessible to patients across Scandinavia and beyond.

The acquisition of StemCare also aligns with Vita 34’s long-term strategy to broaden its customer
base and increase its market share in Europe. By joining forces with StemCare, Vita 34 gains access to
advanced technologies and expertise in stem cell processing, which will further enhance the
company’s research and development efforts. This move will also improve Vita 34’s ability to provide
personalized and cutting-edge treatments, such as cell-based therapies and advanced therapy
medicinal products (ATMPs), to address a range of medical conditions.

Furthermore, this acquisition strengthens Vita 34’s international network, positioning the company
as a key player in the global biotechnology and cell therapy markets. The company aims to lead the
industry by continuously expanding its capabilities and advancing the use of stem cells in medical
treatments. The integration of StemCare Group’s established infrastructure and customer base will
play a vital role in achieving this goal.

With this acquisition, Vita 34 continues to build its reputation as a leading provider of stem cell
solutions, offering high-quality services for both private individuals and healthcare institutions. The
company is committed to advancing the science of regenerative medicine and making these life-
changing therapies available to a growing number of patients around the world.